Announced details
Severe periodontitis, periodontal tissue regeneration, regenerative medicine
Efficacy confirmed in preclinical (animal) studies
8 academic presentations and 2 international patent applications
The parties have jointly pursued the development of periodontal tissue regeneration therapy since 2021, combining Hiroshima University's cell culture technology and clinical expertise with our bio 3D-printing technology.
A national university corporation to which Professor Kajiya Mikito (加治屋 幹人) of Hiroshima University Hospital belongs. Other details are Not disclosed.
2 international patent applications filed (numbers and expiration dates are Not disclosed)
The impact on results for the fiscal year ending December 2026 is currently under review. If any matter requiring disclosure arises, it will be announced promptly.
The company does not address Contract Value / Offering price.
Academic presentations at the Japanese Society for Regenerative Medicine, the Japanese Society of Periodontology and other organizations, and AMED (Japan Agency for Medical Research and Development)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Innovative periodontal tissue regeneration therapy using three-dimensional graft tissue produced with a bio 3D printer |
| Counterparty | Hiroshima University |
| Counterparty overview | A national university corporation to which Professor Kajiya Mikito (加治屋 幹人) of Hiroshima University Hospital belongs. Other details are Not disclosed. |
| Relationship with the Company | The parties have jointly pursued the development of periodontal tissue regeneration therapy since 2021, combining Hiroshima University's cell culture technology and clinical expertise with our bio 3D-printing technology. |
| Applicable area | Severe periodontitis, periodontal tissue regeneration, regenerative medicine |
| Registration number and expiry date | 2 international patent applications filed (numbers and expiration dates are Not disclosed) |
| Quantitative Effects | Efficacy confirmed in preclinical (animal) studies |
| Usage history | 8 academic presentations and 2 international patent applications |
| Impact on Business Performance | The impact on results for the fiscal year ending December 2026 is currently under review. If any matter requiring disclosure arises, it will be announced promptly. |
| Source | Academic presentations at the Japanese Society for Regenerative Medicine, the Japanese Society of Periodontology and other organizations, and AMED (Japan Agency for Medical Research and Development) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate development toward practical application following selection for AMED's FY2026 Research Project for Practical Applications of Regenerative Medicine, etc.